A good example is the inherent resistance of tumours to anti-EGFR antibody and small molecule therapies resulting from the presence of a KRAS mutation and the sensitivity of patients to the gefitinib and erlotinib EGFR inhibitors in non-small cell lung cancer patients with activating EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.